JO
IPSC icon

John Overdeck’s Century Therapeutics IPSC Stock Holding History

John Overdeck’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.61M Buy
2,699,013
+327,583
+14% +$748K ﹤0.01% 1876
2026
Q1 		$5.36M Buy
2,371,430
+875,514
+59% +$1.84M ﹤0.01% 1927
2025
Q4 		$1.49M Buy
1,495,916
+584,470
+64% +$357K ﹤0.01% 2667
2025
Q3 		$454K Buy
911,446
+338,902
+59% +$183K ﹤0.01% 3022
2025
Q2 		$320K Buy
572,544
+486,538
+566% +$261K ﹤0.01% 2766
2025
Q1 		$40.9K Buy
86,006
+19,209
+29% +$14.4K ﹤0.01% 3064
2024
Q4 		$67.5K Buy
+66,797
New +$90.9K ﹤0.01% 3015
2023
Q3 		– Sell
-15,864
Closed -$50.1K – 3078
2023
Q2 		$50.1K Sell
15,864
-21,354
-57% -$68.8K ﹤0.01% 2831
2023
Q1 		$129K Buy
37,218
+1,356
+4% +$5.96K ﹤0.01% 2641
2022
Q4 		$184K Buy
+35,862
New +$339K ﹤0.01% 2409

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

John Overdeck's IPSC Position: Q2 2026 in Review

John Overdeck increased its Century Therapeutics (IPSC) stake by 14% in Q2 2026, buying an estimated $748K and bringing the position to 2,699,013 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

John Overdeck first reported a position in IPSC in Q4 2022 and has held it in 10 quarters since. 98 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • John Overdeck held 2,699,013 shares of Century Therapeutics worth $6.61M as of Q2 2026.
  • John Overdeck bought 327,583 Century Therapeutics shares in Q2 2026, an estimated $748K.
  • Century Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #1876 holding.
  • John Overdeck first reported a position in Century Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • 98 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.